anti-BCMA/GPRC5D bispecific CAR T / Shanghai Yake Biotech, Xuzhou Medical University - LARVOL DELTA

New frontier observations | Low-age CAR-T is applied for listing; HPV market reaches its peak, and cooperation between Chinese and foreign companies ends [Google translation] (Sohu.com) - P2 | N=30 | NCT05509530 | "On July 23, the results of the Phase I clinical trial of the BCMA/GPRC5D bispecific CAR-T cell therapy technology developed by Shanghai Yaco Biotechnology Co., Ltd. for the treatment of relapsed and refractory multiple myeloma were published in the industry-renowned journal 'The Lancet Haematology'. The clinical trial was conducted by a medical team from the Institute of Hematology of Xuzhou Medical University....According to the paper, the clinical trial included a total of 21 patients , with a total remission rate of 86%. Among the 12 patients who received the optimal dose of 2 x 10^6/kg, the total remission rate reached 91.7% (11/12), complete remission/strict complete remission reached 75% (9/12), and very good partial remission was 16.7% (2/12)."

P2 data • Hematological Malignancies • Multiple Myeloma • Oncology